All you need to know about Biomarkers - Webinar

Please feel free to read, share your thoughts, your stories and connect with others!
User avatar
JJH
Posts: 408
Joined: Mon Apr 24, 2017 7:26 am

All you need to know about Biomarkers - Webinar

Postby JJH » Mon Sep 11, 2017 12:53 am

"The darkest hour is just before the dawn" - Thomas Fuller (1650)
●●●

rp1954
Posts: 1853
Joined: Mon Jun 13, 2011 1:13 am

Re: All you need to know about Biomarkers - Webinar

Postby rp1954 » Mon Sep 11, 2017 6:43 pm

Thanks. I watched this after the webinar so I didn't get to ask any questions.
The post webinar link changed to here

This webinar leans toward PD-1 research,testing and education, and also recent genetic testing . He also noted that stage 1-3 patients with PD-1 indications may substantially benefit from 1-2 anti-PD1 treatments. He favorably noted the "liquid biopsy" tests in some situations now and a favorable future.

The webinar did have two important, cheap notes: First, that baby aspirin appears to have had a 90% reduction in recurrence in stage 1-3 patients who had PIK3CA mutations. Second, that right sided, Kras-wild CRC patients tended to flunk EGFR (erbitux, vectibix) treatment - right sided is cheap information. Nothing on common biomarkers like CA19-9 for KRAS, BRAF mutants, or targeting cheap drugs like cimetidine, celecoxib, and metformin.

He did acknowledge in the Q&A that biomarkers markedly change with time in metastatic cancer. My wife has had separate peaks in CEA, AFP and CA19-9 that had to be pounded down by multimodal attack. In the last six years, rises in CA19-9 and AFP mostly with changes in supplements and IV C, but prior credit to cimetidine, 5FU, and celecoxib. My wife's current CEA readings have been lower 2.x, near her postsurgical floor values on metronomic immunochemo, ca 1/6th - 1/9th of prior CEA peaks in the first 13 months.
Last edited by rp1954 on Mon Sep 11, 2017 6:50 pm, edited 2 times in total.
watchful, active researcher and caregiver for stage IVb/c CC. surgeries 4/10 sigmoid etc & 5/11 para-aortic LN cluster; 8 yrs immuno-Chemo for mCRC; now no chemo
most of 2010 Life Extension recommendations and possibilities + more, some (much) higher, peaking ~2011-12, taper chemo to almost nothing mid 2018, IV C-->2021. Now supplements

mpbser
Posts: 953
Joined: Wed Apr 19, 2017 11:52 am

Re: All you need to know about Biomarkers - Webinar

Postby mpbser » Mon Sep 11, 2017 6:49 pm

Thanks for posting this JJH and for the synopsis rp1954

I actually happened to be reviewing my husband's Oncopanel this evening and this came in very handy!
Wife 4/17 Dx age 45
5/17 LAR
Adenocarcinoma
low grade
1st primary T3 N2b M1a
Stage IVA
8/17 Sub-total colectomy
2nd primary 5.5 cm T1 N0
9 of 96 nodes
CEA: < 2.9
MSS
Lynch no; KRAS wild
Immunohistochemsistry Normal
Fall 2017 FOLFOX shrank the 1 met in liver
1/18 Liver left hepatectomy seg 4
5/18 CT clear
12/18 MRI 1 liver met
3/7/19 Resection & HAI
4/1/19 Folfiri & FUDR
5/13/19 HAI pump catheter dislodge, nearly bled to death
6-7 '19 5FU 4 cycles
NED

NHMike
Posts: 2555
Joined: Fri Jul 21, 2017 3:43 am

Re: All you need to know about Biomarkers - Webinar

Postby NHMike » Mon Sep 11, 2017 6:53 pm

rp1954 wrote:Thanks. I watched this after the webinar so I didn't get to ask any questions.
The post webinar link changed to here

This webinar leans toward PD-1 research,testing and education, and also recent genetic testing . He also noted that stage 1-3 patients with PD-1 indications may substantially benefit from 1-2 anti-PD1 treatments. He favorably noted the "liquid biopsy" tests in some situations now and a favorable future.

The webinar did have two important, cheap notes: First, that baby aspirin appears to have had a 90% reduction in recurrence in stage 1-3 patients who had PIK3CA mutations. Second, that right sided, Kras-wild CRC patients tended to flunk EGFR (erbitux, vectibix) treatment - right sided is cheap information. Nothing on common biomarkers like CA19-9 for KRAS, BRAF mutants, or targeting cheap drugs like cimetidine, celecoxib, and metformin.

He did acknowledge in the Q&A that biomarkers markedly change with time in metastatic cancer. My wife has had separate peaks in CEA, AFP and CA19-9 that had to be pounded down by multimodal attack. In the last six years, rises in CA19-9 and AFP mostly with changes in supplements and IV C, but prior credit to cimetidine, 5FU, and celecoxib. My wife's current CEA readings have been lower 2.x, near her postsurgical floor values on metronomic immunochemo, ca 1/6th - 1/9th of prior CEA peaks in the first 13 months.



Thanks for the summary.
6/17: ER rectal bleeding; Colonoscopy
7/17: 3B rectal. T3N1bM0. 5.2 4.5 4.3 cm. Lymphs: 6 x 4 mm, 8 x 6, 5 x 5
7/17-9/17: Xeloda radiation
7/5: CEA 2.7; 8/16: 1.9; 11/30: 0.6; 12/20 1.4; 1/10 1.8; 1/31 2.2; 2/28 2.6; 4/10 2.8; 5/1 2.8; 5/29 3.2; 7/13 4.5; 8/9 2.8, 2/12 1.2
MSS, KRAS G12D
10/17: 2.7 2.2 1.6 cm (-90%). Lymphs: 3 x 3 mm (-62.5%), 4 x 3 (-75%), 5 x 3 (-40%). 5.1 CM from AV
10/17: LAR, Temp Ileostomy, Path Complete Response
CapeOx (8) 12/17-6/18
7/18: Reversal, Port Removal
2/19: Clean CT

SweetC80
Posts: 103
Joined: Fri Sep 01, 2017 1:28 pm

Re: All you need to know about Biomarkers - Webinar

Postby SweetC80 » Wed Sep 13, 2017 8:26 am

Sounds interesting and informative, thanks for posting.
My Mom
12/16 Stage IIIb Rectal Ca CEA 1.2
1/17-2/17 Chemoradiation CEA 4.4
5/17 Entire Colon, Rectum & Anus removed Perm Ileostomy Bag
7/17 FOLFOX
9/17 Stage IVb 9cm Liver Met & 7mm Lung Nodule CEA 197
9/17 FOLFIRI CEA 160
10/17 Confirmed KRAS Pos CEA 210
11/17 Met growths Liver 10cm & Lung 8mm CEA 425
12/17 FOLFOX again Met growths Liver 13cm & Lung 1cm CEA 405
12/17 Xifaxan due to Hepatic Encephalopathy
12/17 New 2cm liver Met
1/18 CEA 992
2/8/18 Passed Peacefully

mpbser
Posts: 953
Joined: Wed Apr 19, 2017 11:52 am

Re: All you need to know about Biomarkers - Webinar

Postby mpbser » Thu Sep 14, 2017 11:16 am

I just wish the presenter named the "better" biomarker detectable in blood tests that can be used to detect recurrence. I realize it's still in development, but I'd like to know what it is.
Wife 4/17 Dx age 45
5/17 LAR
Adenocarcinoma
low grade
1st primary T3 N2b M1a
Stage IVA
8/17 Sub-total colectomy
2nd primary 5.5 cm T1 N0
9 of 96 nodes
CEA: < 2.9
MSS
Lynch no; KRAS wild
Immunohistochemsistry Normal
Fall 2017 FOLFOX shrank the 1 met in liver
1/18 Liver left hepatectomy seg 4
5/18 CT clear
12/18 MRI 1 liver met
3/7/19 Resection & HAI
4/1/19 Folfiri & FUDR
5/13/19 HAI pump catheter dislodge, nearly bled to death
6-7 '19 5FU 4 cycles
NED


Return to “Colon Talk - Colon cancer (colorectal cancer) support forum”



Who is online

Users browsing this forum: cannabisexpert, Google [Bot] and 139 guests